Kimberly-Clark Corp. (NYSE:KMB) has provided investors with reliable income increases for decades.
In fact, the company is one of the 51 Dividend Aristocrats, which can all be seen here.
Kimberly-Clark pays one of the safest dividends in the market, yields close to 3%, offers mid-single-digit payout growth and sells recession-resistant products.
All of these investment qualities are appealing for retired investors living on dividends.
Like many other large consumer brand multinationals however, Kimberly-Clark is battling foreign currency headwinds, slower growth in developed markets and an evolving competitive landscape.
Let’s take a closer look at Kimberly-Clark to see why it deserves to be a core position in our Top 20 Dividend Stocks portfolio.
Business overview
Kimberly-Clark has been in business since 1928 and has grown into one of the largest global manufacturers of various tissue and hygiene products.
Top Safest Stocks For 2019: Endologix, Inc.(ELGX)
Advisors' Opinion:- [By Max Byerly]
Endologix (NASDAQ:ELGX)‘s stock had its “hold” rating restated by investment analysts at Oppenheimer in a report issued on Wednesday.
- [By Stephan Byrd]
Endologix (NASDAQ:ELGX) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Wednesday.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Endologix (ELGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Here are some of the news headlines that may have impacted Accern’s analysis:
Get Endologix alerts: Endologix Reports Positive One-Year Results From the Ovation LUCY Study (dicardiology.com) Endologix, Inc. to Announce Second Quarter 2018 Financial Results on August 9, 2018 (finance.yahoo.com) Stock Under Active Eyes: Endologix, Inc. (ELGX) (bitcoinpriceupdate.review) Endologix, Inc. (ELGX) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com) Endologix Inc. to Post FY2016 Revenue of ($0.71) Per Share, Leerink Swann Forecasts (ELGX) (bharatapress.com)NASDAQ:ELGX traded down $0.09 on Tuesday, hitting $5.42. 4,339 shares of the stock were exchanged, compared to its average volume of 483,122. The firm has a market capitalization of $462.06 million, a PE ratio of -11.31 and a beta of 0.44. The company has a debt-to-equity ratio of 3.58, a current ratio of 2.13 and a quick ratio of 1.37. Endologix has a fifty-two week low of $3.75 and a fifty-two week high of $6.72.
- [By Brian Orelli]
Shares of Endologix (NASDAQ:ELGX) were down 37% on Friday after the medical device maker announced disappointing earnings at market close on Thursday. Specifically, revenue decreased 7.9% year over year due to lower U.S. sales of AFX, its endovascular system to treat abdominal aortic aneurysms, and softness in Latin America.
Top Safest Stocks For 2019: National Health Investors, Inc.(NHI)
Advisors' Opinion:- [By Shane Hupp]
Virginia Retirement Systems ET AL lifted its position in shares of National Health Investors, Inc. (NYSE:NHI) by 10.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,300 shares of the real estate investment trust’s stock after acquiring an additional 10,700 shares during the period. Virginia Retirement Systems ET AL owned approximately 0.28% of National Health Investors worth $7,826,000 as of its most recent filing with the Securities & Exchange Commission.
- [By Shane Hupp]
Get a free copy of the Zacks research report on National Health Investors (NHI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Shane Hupp]
Get a free copy of the Zacks research report on National Health Investors (NHI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Get a free copy of the Zacks research report on National Health Investors (NHI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Motley Fool Transcribers]
National Health Investors Inc (NYSE:NHI)Q4 2018 Earnings Conference CallFeb. 19, 2019, 12:00 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Colleen Schaller -- Director, Investor Relations
Top Safest Stocks For 2019: TheStreet, Inc.(TST)
Advisors' Opinion:- [By Shane Hupp]
WARNING: “TheStreet, Inc. (TST) Given $2.83 Consensus Target Price by Analysts” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3375008/thestreet-inc-tst-given-2-83-consensus-target-price-by-analysts.html.
- [By Logan Wallace]
Press coverage about TheStreet (NASDAQ:TST) has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TheStreet earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the information services provider an impact score of 48.5783795459236 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on TheStreet (TST)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By ]
TheStreet (TST) caught up with PayPal (PYPL) CEO Dan Schulman on the latest Jolt podcast to chat about a range of topics. Of course a talk about the future of physical cash came up.
Top Safest Stocks For 2019: Argo Group International Holdings Ltd.(AGII)
Advisors' Opinion:- [By Joseph Griffin]
Barclays PLC raised its stake in Argo Group (NASDAQ:AGII) by 25.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,691 shares of the insurance provider’s stock after acquiring an additional 1,754 shares during the period. Barclays PLC’s holdings in Argo Group were worth $499,000 as of its most recent SEC filing.
- [By Stephan Byrd]
Argo Group (NASDAQ: AGII) and Stewart Information Services (NYSE:STC) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.
- [By Max Byerly]
Lord Abbett & CO. LLC purchased a new position in shares of Argo Group (NASDAQ:AGII) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 840,251 shares of the insurance provider’s stock, valued at approximately $48,230,000. Lord Abbett & CO. LLC owned approximately 2.49% of Argo Group as of its most recent filing with the SEC.
Top Safest Stocks For 2019: Genfit SA (GNFTF)
Advisors' Opinion:- [By Keith Speights]
French drugmaker Genfit (NASDAQOTH:GNFTF) expects to report interim results from a phase 3 study of elafibranor in treating NASH later in 2019. The company could be set to file for regulatory approval in the NASH indication by late 2020 or early 2021. Elafibranor could potentially be viewed as more effective and safer than Ocaliva based on earlier clinical results. Genfit is also evaluating elafibranor in treating PBC, with positive phase 2 results announced in December 2018.
- [By ]
Here's what we wrote: "With GR-MD-02, Galectin is also targeting a different spectrum of NASH. The company's programs with GR-MD-02 are focusing on NASH treatment in individuals with advanced fibrosis and cirrhosis. As we mentioned before, Genfit (OTCPK:GNFTF) and Intercept (ICPT) are targeting what can be termed as the "sweet spot" of the NASH spectrum. Galecctin is one of the few companies targeting advanced stage of the disease. This makes it both an interesting and at the same time risky bet in the NASH space."
- [By ]
This phase 2 data for Madrigal was phenomenal, which is why I think it will do well in a phase 3 trial. The other side of the trade is that Intercept Pharmaceuticals (ICPT) and Genfit (OTCPK:GNFTF) are further along with phase 3 trials, which are expected to read out NASH results by 2019/2020. Intercept has a good drug with Ocaliva, however, it suffers from toxicity issues when Doctors prescribe higher than necessary dosing. On the flip side, Ocaliva has shown a greater difference in fibrosis reduction for NASH in its phase 2 FLINT trial compared to MGL-3196. What do I mean by that? Well, as you can see above MGL-3196 obtained a fibrosis reduction in NASH patients of 29% compared to 23% for those on placebo creating a difference of only 6%. If you look at Ocaliva from the FLINT trial, from Intercept Pharmaceuticals, it had a fibrosis reduction of 35% compared to 19% of those NASH patients on placebo. It is just something to keep in mind. I still believe that MGL-3196 will eventually be approved. The question that should be asked is how well will it do compared to other competitors in the same space with better fibrosis reductions? That will be key, because NASH causes fibrosis (scarring) of the liver. Fibrosis eventually turns into cirrhosis of the liver, which can eventually lead to liver failure. That's why, in my opinion, a drug that will have the most impact on NASH will be one that shows a major reduction in fibrosis. The good news is that the NASH market is expected to reach between $20 to $30 billion in the coming years. It is a large market for plenty of players in this space. The other endpoints are important as well, but in a competitive market such as NASH, fibrosis reduction will make the difference in terms of more sales. This is just an important factor to keep in mind.
- [By SEEKINGALPHA.COM]
In a recent article, we discussed what makes Genfit's (OTCPK:GNFTF) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranor's mechanism of action and the potential it has shown in clinical stages, we see a strong chance of approval if the pivotal Phase 3 study succeeds. In this article, we will briefly discuss the chances of Elafibranor's success in clinical stages and Genfit's valuation based on the potential of its lead product candidate. We will briefly also discuss the risks to the investment thesis.
No comments:
Post a Comment